Last week, the World Health Organization announced that Covid-19 no longer qualifies as a global emergency, marking an end - albeit a symbolic one - to the pandemic.

Pfizer, maker of one of the most-used Covid-19 jabs and an antiviral pill, hit a record-breaking $100 billion in revenues in 2022, spurred by earnings from those treatments.

As the pandemic wanes and demand for treatments drops off, the New York-headquartered pharmaceuticals company is in a "transition year", chief executive Albert Bourla said on a first-quarter earnings call.

Patrick van der Loo, a regional president who oversees the Middle East, Russia and Africa, talks to host Kelsey Warner this week about what a transition means for the world's biggest pharmaceutical company by revenue, how the pandemic changed drug development cycles and what the Gulf's potential is for taking a piece of the booming life sciences industry.

In this episode:

• Pfizer drops sales guidance after posting 47% jump in Q4 profits

Subscribe to Business Extra for free to receive new episodes every week